Csl (QX) Aktie - CSLLY

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Current Price

79,48

Gebot

79,38

Fragen

80,81

Volumen

122.793

79,06 Tagesbereich 80,02

77,37 52-Wochen-Bereich 109,00

Marktkapitalisierung

76,969B

Handelsende

80,28

Handelsbeginn

79,09

Letzte Trade

671

79.48

Letzter Handelszeitpunkt

Finanzvolumen

US$ 9.754.838

VWAP

79,4413

Durchschnittliches Volumen (3 Mio.)

83.657

Ausgegebene Aktien

968.413.124

Dividendenrendite

Kurs-Gewinn-Verhältnis

92,52

Gewinn pro Aktie (EPS)

2,73

Erlöse

14,69B

Nettogewinn

2,64B

CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. CSL is a leading global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology.

Sektor

Biological Pds,ex Diagnstics

Branche

Biological Pds,ex Diagnstics

Website

www.csl.com.au

Hauptsitz

Melbourne, Victoria, Aus

Gegründet

1916

Csl Ltd (QX) is listed in the Biological Pds,ex Diagnstics sector of the OTCMarkets with ticker CSLLY. The last closing price for Csl (QX) was US$80,28. Over the last year, Csl (QX) shares have traded in a share price range of US$ 77,37 to US$ 109,00.

Csl (QX) currently has 968.413.124 shares in issue. The market capitalisation of Csl (QX) is US$77,74 billion. Csl (QX) has a price to earnings ratio (PE ratio) of 92.52.

Form 3 - Initial statement of beneficial ownership of securities

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient Awards Program Supports Novel Research of Immunoglobulin Therapy for...

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015 PR Newswire TORONTO...

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A PR Newswire TORONTO, June 24...

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers Panel of experts examines how...

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress PR Newswire KING OF PRUSSIA, Pa., June 16, 2015 More...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients...

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients with Alpha-1...

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0.49	0.620331687555	78.99	80.67	78.35	80746	79.49930275	DR
4	-3.049	-3.69445891747	82.529	84.25	77.75	75948	80.64797087	DR
12	-9.855	-11.0315106061	89.335	90.04	77.37	83657	83.69634112	DR
26	-19.628	-19.8046575453	99.108	101.44	77.37	69370	86.96919044	DR
52	-11.52	-12.6593406593	91	109	77.37	48622	89.49553173	DR
156	-21.52	-21.3069306931	101	110.25	71.51	64901	90.73917851	DR
260	-2.17	-2.65768524189	81.65	117.98	71.51	58969	94.87440296	DR

CSLLY - Frequently Asked Questions (FAQ)

What is the current Csl (QX) share price?

The current share price of Csl (QX) is US$ 79,48

How many Csl (QX) shares are in issue?

Csl (QX) has 968.413.124 shares in issue

What is the market cap of Csl (QX)?

The market capitalisation of Csl (QX) is USD 77,74B

What is the 1 year trading range for Csl (QX) share price?

Csl (QX) has traded in the range of US$ 77,37 to US$ 109,00 during the past year

What is the PE ratio of Csl (QX)?

The price to earnings ratio of Csl (QX) is 92,52

What is the cash to sales ratio of Csl (QX)?

The cash to sales ratio of Csl (QX) is 16,64

What is the reporting currency for Csl (QX)?

Csl (QX) reports financial results in USD

What is the latest annual turnover for Csl (QX)?

The latest annual turnover of Csl (QX) is USD 14,69B

What is the latest annual profit for Csl (QX)?

The latest annual profit of Csl (QX) is USD 2,64B

What is the registered address of Csl (QX)?

The registered address for Csl (QX) is 655 ELIZABETH STREET, MELBOURNE, VICTORIA, 3000

What is the Csl (QX) website address?

The website address for Csl (QX) is www.csl.com.au

Which industry sector does Csl (QX) operate in?

Csl (QX) operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
EGSEEvergreen Sustainable Enterprises Inc (CE)	US$ 0,0008 (79.900,00%)	115
HLLPFHello Pal International Inc (CE)	US$ 0,0005 (49.900,00%)	1.000
SBESSouth Beach Spirits Inc (CE)	US$ 0,0002 (19.900,00%)	6M
BETSFBit Brother Ltd (CE)	US$ 0,04 (13.233,33%)	140
RKFLRocketFuel Blockchain Inc (CE)	US$ 0,01 (9.900,00%)	7k
ZMMHZhongMin Meihao Holding Company Ltd (CE)	US$ 0,000001 (-99,98%)	225k
STTOSITO Mobile Ltd (CE)	US$ 0,0004 (-99,76%)	278
LSDIFLucy Scientific Discovery Inc (CE)	US$ 0,000001 (-99,50%)	1.000
INTKIndustrial Nanotech Inc (PK)	US$ 0,000001 (-99,33%)	3,03M
NVOSNovo Integrated Sciences Inc (CE)	US$ 0,0005 (-99,07%)	11,21k
KGKGKona Gold Beverage Inc (PK)	US$ 0,0001 (-25,93%)	532,65M
ASIIAccredited Solutions Inc (PK)	US$ 0,0005 (49,25%)	524,57M
HMBLHUMBL Inc (PK)	US$ 0,0003 (0,00%)	284,16M
GTVHGolden Triangle Ventures Inc (PK)	US$ 0,0006 (50,00%)	218,02M
TPTWTPT Global Tech Inc (PK)	US$ 0,0002 (0,00%)	160,5M

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Csl Ltd (QX) (CSLLY)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Csl Ltd (QX)

CSLLY Neueste Nachrichten

Form 3 - Initial statement of beneficial ownership of securities

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients...

National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award

Science, Information, And Technology Driving Evolution Of Global Healthcare

CSL Behring Awards Young Researchers Around the World to Advance Coagulation Science

CSLLY - Frequently Asked Questions (FAQ)

Beweger

CSLLY Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Csl Ltd (QX) (CSLLY) Börsenkurse

Csl Ltd (QX) (CSLLY)

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Wichtige Statistiken und Details

Über Csl Ltd (QX)

CSLLY Neueste Nachrichten

Form 3 - Initial statement of beneficial ownership of securities

CSL Behring Announces the 2015 Interlaken Leadership Awards Recipient

CSL Behring Presents rIX-FP for Hemophilia B Phase III Data Evaluating Efficacy, Safety and Improved Dosing at ISTH 2015

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

Defining And Differentiating The Value Of Therapies Used To Treat Rare Disease Patients Is A Challenge For Payers

CSL Behring to Present Pivotal Data for rVIII-SingleChain and rIX-FP at 2015 ISTH Congress

Important New Findings Published in The Lancet Support the Use of Zemaira® [Alpha1-Proteinase Inhibitor (Human)] in Patients...

National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award

Science, Information, And Technology Driving Evolution Of Global Healthcare

CSL Behring Awards Young Researchers Around the World to Advance Coagulation Science

CSLLY - Frequently Asked Questions (FAQ)

Beweger

CSLLY Finanzen

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen